Mobile

A double-blind, placebo-contolled study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 with or without a drug called ribavirin in people with hepatitis C v...

Update Il y a 4 ans
Reference: EUCTR2012-005522-29

A double-blind, placebo-contolled study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 with or without a drug called ribavirin in people with hepatitis C virus (HCV) that have not been treated before. "Experimental" means that they have not been approved by any regulatory agency for sale to the public

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objectives of this study are to compare the safety of the combination of ABT-450/r/ABT-267 and ABT-333 administered with and without RBV for 12 weeks of treatment with ABT-450/r/ABT-267 and ABT-333 administered with and without RBV compared to the historical SVR rate of telaprevir plus pegIFN and RBV therapy in treatment-naive HCV genotype (GT) 1a-infected adults without cirrhosis.

Inclusion criteria

  • Chronic Hepatitis C Infection

Links